Literature DB >> 1381211

Fulminant hepatic failure in non-Hodgkin lymphoma patients treated with chemotherapy.

L T Soh1, P T Ang, I Sng, E J Chua, Y W Ong.   

Abstract

Chemotherapy is the mainstay of therapy for patients with non-Hodgkin lymphoma. Among side-effects associated with the use of chemotherapy, immunosuppression is one which can be potentially fatal. In hepatitis B carriers, immunosuppression permits widespread infection of the hepatocytes and its subsequent withdrawal causes an "immunological rebound" leading to massive necrosis of hepatocytes. 4 patients who died of fulminant hepatitis following chemotherapy are reported. These were patients with positive hepatitis B serology. Caution is advised when treating non-Hodgkin lymphoma in patients from hepatitis B endemic regions.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1381211     DOI： 10.1016/0959-8049(92)90513-2

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0959-8049            Impact factor:   9.162


  10 in total

Review 1.  Dose adaptation of antineoplastic drugs in patients with liver disease.

Authors:  Lydia Tchambaz; Chantal Schlatter; Max Jakob; Anita Krähenbühl; Peter Wolf; Stephan Krähenbühl
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

2.  Acute exacerbation of hepatitis due to reactivation of hepatitis B virus with mutations in the core region after chemotherapy for malignant lymphoma.

Authors:  T Sato; J Kato; J Kawanishi; K Kogawa; M Ohya; S Sakamaki; Y Niitsu
Journal:  J Gastroenterol       Date:  1997-10       Impact factor: 7.527

3.  Hepatitis B reactivation after chemotherapy: two decades of clinical research.

Authors:  George K K Lau
Journal:  Hepatol Int       Date:  2008-03-05       Impact factor: 6.047

4.  Molecular epidemiology of an outbreak of fulminant hepatitis B.

Authors:  N Petrosillo; G Ippolito; L Solforosi; P E Varaldo; M Clementi; A Manzin
Journal:  J Clin Microbiol       Date:  2000-08       Impact factor: 5.948

5.  Recovery from life-threatening, corticosteroid-unresponsive, chemotherapy-related reactivation of hepatitis B associated with lamivudine therapy.

Authors:  F ter Borg; S Smorenburg; R A de Man; R C Rietbroek; R A Chamuleau; E A Jones
Journal:  Dig Dis Sci       Date:  1998-10       Impact factor: 3.199

6.  Association between hepatitis B virus and pancreatic cancer.

Authors:  Manal M Hassan; Donghui Li; Adel S El-Deeb; Robert A Wolff; Melissa L Bondy; Marta Davila; James L Abbruzzese
Journal:  J Clin Oncol       Date:  2008-10-01       Impact factor: 44.544

7.  Reactivation of hepatitis B virus infection with cytotoxic therapy in non-Hodgkin's lymphoma.

Authors:  M Ozguroglu; A Bilici; H Turna; S Serdengecti
Journal:  Med Oncol       Date:  2004       Impact factor: 3.064

8.  Prophylactic Lamivudine to Improve the Outcome of Breast Cancer Patients With HBsAg Positive During Chemotherapy: A Meta-Analysis.

Authors:  Yihu Zheng; Shengchu Zhang; Hooi Min Tan Grahn; Chao Ye; Zheng Gong; Qiyu Zhang
Journal:  Hepat Mon       Date:  2013-04-01       Impact factor: 0.660

9.  Rituximab administration and reactivation of HBV.

Authors:  Yutaka Tsutsumi; Reiki Ogasawara; Yusuke Kamihara; Shinichi Ito; Yoshiya Yamamoto; Junji Tanaka; Masahiro Asaka; Masahiro Imamura
Journal:  Hepat Res Treat       Date:  2010-12-01

10.  Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy.

Authors:  W Yeo; B Zee; S Zhong; P K S Chan; W-L Wong; W M Ho; K C Lam; P J Johnson
Journal:  Br J Cancer       Date:  2004-04-05       Impact factor: 7.640
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.